A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker During Hepatocellular Carcinoma Immunotherapy
The chemotherapeutics sorafenib and regorafenib inhibit shedding of MHC class I-related chain A (MICA) from hepatocellular carcinoma (HCC) cells by suppressing a disintegrin and metalloprotease 9 (ADAM9). MICA is a ligand for natural killer (NK) group 2 member D (NKG2D) and is expressed on tumor cel...
Main Authors: | Sooyeon Oh, YoungJoon Park, Hyun-Jung Lee, Jooho Lee, Soo-Hyeon Lee, Young-Seok Baek, Su-Kyung Chun, Seung-Min Lee, Mina Kim, Young-Eun Chon, Yeonjung Ha, Yuri Cho, Gi Jin Kim, Seong-Gyu Hwang, KyuBum Kwack |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/3/745 |
Similar Items
-
A Disintegrin and Metalloproteinase Protein 8 (ADAM 8) in Autism Spectrum Disorder: Links to Neuroinflammation
by: Al-Ayadhi L, et al.
Published: (2023-08-01) -
New insight into the role of the ADAM protease family in breast carcinoma progression
by: Sepideh Aliniaye Navasatli, et al.
Published: (2024-02-01) -
ADAM and ADAMTS Proteins, New Players in the Regulation of Hepatocellular Carcinoma Microenvironment
by: Nathalie Théret, et al.
Published: (2021-03-01) -
Relevance of A Disintegrin and Metalloproteinase Domain-Containing (ADAM)9 Protein Expression to Bladder Cancer Malignancy
by: Michika Moriwaki, et al.
Published: (2022-06-01) -
ADAM10 and ADAM17, Major Regulators of Chronic Kidney Disease Induced Atherosclerosis?
by: Sanne L. Maas, et al.
Published: (2023-04-01)